https://scholars.lib.ntu.edu.tw/handle/123456789/528504
標題: | Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens | 作者: | Jean S.-S. PO-REN HSUEH |
公開日期: | 2011 | 卷: | 12 | 期: | 14 | 起(迄)頁: | 2145-2148 | 來源出版物: | Expert Opinion on Pharmacotherapy | 摘要: | Nosocomial pneumonia (including ventilator-associated pneumonia; VAP), a consistently difficult-to-treat entity, is frequently caused by multidrug-resistant (MDR) or pandrug-resistant (PDR) bacteria. Given the high mortality rates caused by drug-resistant bacteria and the difficulty of developing new potent antibiotics to target the problematic pathogens, combination regimens are under ardent evaluation as new strategies to overcome increasing drug resistance. Adjustment of the administration method of certain β-lactams (meropenem, or imipenem/cilastatin), or combination of tigecycline with some agents, may show promise with regard to successful management of MDR or PDR Acinetobacter baumannii pneumonia. Additionally, vancomycin plus rifampicin is an effective regimen against nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) responding poorly to vancomycin monotherapy. The clinical appropriateness of parenteral colistin against pneumonia caused by MDR A. baumannii has been established in a clinical trial. Facing the decline of clinical vancomycin efficacy after initial use, linezolid might be the drug of choice with regard to the treatment of MRSA-VAP. The role of tigecycline monotherapy for the management of nosocomial pneumonia caused by MRSA and extended-spectrum β-lactamase-producing Enterobacteriaceae needs to be cautiously evaluated. ? 2011 Informa UK, Ltd. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/528504 | ISSN: | 1465-6566 | DOI: | 10.1517/14656566.2011.599320 | SDG/關鍵字: | amikacin; antiinfective agent; carbapenem; cilastatin plus imipenem; colistin; dalfopristin plus quinupristin; ertapenem; extended spectrum beta lactamase; iclaprim; levofloxacin; linezolid; meropenem; rifampicin; sulbactam; telavancin; tigecycline; vancomycin; Acinetobacter infection; antibiotic resistance; antimicrobial therapy; drug bioavailability; drug efficacy; drug megadose; drug safety; drug treatment failure; Enterobacteriaceae infection; Gram negative infection; hospital acquired pneumonia; human; loading drug dose; maintenance drug dose; maximum plasma concentration; methicillin resistant Staphylococcus aureus infection; minimum inhibitory concentration; monotherapy; multidrug resistance; nonhuman; review; ventilator associated pneumonia; Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Pneumonia, Bacterial; Staphylococcal Infections; Staphylococcus aureus |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。